Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Neurology Clinical Trials Market size was over USD 6.1 billion in 2024 and is estimated to reach USD 12 billion by the end of 2037, expanding at a CAGR of 5.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of neurology clinical trials is assessed at USD 6.4 billion.
The enlarging patient pool of neurologically impaired habitats across the world is pushing public and private institutions to innovate new treatment approaches, boosting the neurology clinical trials market. According to a report from the Institute of Health Metrics and Evaluation (IHME), published in March 2024, neurological conditions took around 443.0 million healthy lives worldwide in 2021. It also mentioned that over 43.0% of the global population was identified to be suffering from these disorders in the same year, accounting for 3.4 billion. Thus, more pharma pioneers are growing interest in developing novel therapeutics for the wide spectrum of conditions related to the central nervous system (CNS). Subsequently, the investments and engagements in this sector are rising.
Further, as the industry associated with this medical category emphasizes, the demand in the neurology clinical trials market inflates. On this note, in March 2023, IQVIA projected the size of the CNS industry to be USD 169.0 billion by 2027. This reciprocates the heightened activity in clinical R&D and findings. However, the financial toxicity, built during the elongated development and approval processes, results in a hike in product pricing. As per NLM estimation from a 2022 article, the tentative median capitalized payers' pricing of R&D for each approved neurologic agent was USD 1.5 billion.
This creates an economic barrier for patients. For instance, the annual expense on the generic formulation of Emflaza (deflazacort), used to treat Duchenne muscular dystrophy (DMD), was USD 2000.0 in 2022. Although the cost per year for this drug in the U.S., after the FDA approval, turned out to be USD 89,000.0, as per NLM survey. This issue is further addressed by the technological innovations and upgradation in laboratory operations. In addition, the introduction of contractual R&D services is contributing to reducing developmental costs through their optimized techniques and infrastructure.
Neurology Clinical Trials Market: Growth Drivers and Challenges
Growth Drivers
- Government and institutional investments and efforts: The tendency of various research institutions in bringing breakthroughs in neuroscience, particularly for resistant diseases, is bolstering adoption in the neurology clinical trials market. Several government organizations are now showing interest in creating a reliable platform for seamless testing of medications, fostering scopes of progress. For instance, in July 2023, the National Institutes of Health (NIH) commenced the evaluation process on a total of 11 newly introduced, potentially effective extended-COVID therapeutics. The launch called for identifying suitable drugs, biologics, medical devices, and other therapies through their adaptive study design, based on the learnings from the RECOVER initiative.
- Improvement in laboratory operations: Enhanced and improved outcomes due to enrollments from the neurology clinical trials market, are inspiring more companies to invest. For instance, in August 2024, Design Therapeutics opted for an observational biomarker study to prepare for the commercial launch of its investigational agent, DT-216P2, treating Friedreich ataxia (FA). This method allowed the company to evaluate the FA biomarker assays individually in participants, identifying probable variation in FXN protein levels. Such detailed assessments are evidence of better precision and efficacy. Further, advancements in neuroimaging, biomarkers, and genetic testing are crafting new avenues with a better understanding and treatment approach.
Challenges
- The complexity and disparity in studies: Operations in the neurology clinical trials market are highly complex and time-consuming. Variation in symptom appearance and disease progression often complicate the process of detecting the drug’s effectiveness. This makes it difficult for companies to attain compliance with standardized treatment protocols due to inconsistent results. It may also impact the recruitment process of sufficient participating candidates and laboratory professionals, hindering continuity in trials and asset supply.
- Diverse regulatory and consumer preference: Besides the variability in disease type, the diversity in approval criteria across different regions may also limit investments in the neurology clinical trials market. Navigating the whole process according to the individual regulatory frameworks may become a challenge. In addition, the indifferent product choices among patients may make it hard for companies to maintain compliance while addressing every requirement. This may result in delayed launch and additional production cost, disrupting the marketing strategy of manufacturers.
Neurology Clinical Trials Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 6.1 billion |
|
Forecast Year Market Size (2037) |
USD 12 billion |
|
Regional Scope |
|
Neurology Clinical Trials Segmentation
Indication (Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Others)
Based on indication, the epilepsy segment is predicted to account for neurology clinical trials market share of around 25.4% by 2037. Growth in this segment is pledged with its notable contribution in the magnifying burden of illnesses around the globe. On this note, WHO reported that epilepsy accounted for health disruption in approximately 50.0 million people globally till February 2024, with a total annual diagnosis of 5.0 million cases. It further mentioned that 50.0% of these incidences do not present any underlying cause, although 70.0% of these are manageable with adequate therapies. These figures signify a demanding and enlarging patient pool, pushing pharma producers to be involved with rigorous research and development for introducing innovative solutions.
Phase (Phase I, Phase II, Phase III, Phase IV)
In terms of phase, the phase II segment is predicted to hold a significant share in the neurology clinical trials market throughout the forecasted timeframe. Major key aspects of the drug development process, such as efficacy testing, safety monitoring, and dose optimization, are performed under this stage. This makes it the most critical portion for this sector, where a larger cohort of participants (patients) is involved. The elongated duration of this stage also garners a remarkable revenue for this segment. For instance, in January 2023, IQVIA revealed that 31.0% (highest) and 26.0% (2nd highest) of the total industrial sponsors for the Alzheimer’s and Parkinson’s therapeutic development pipeline were dedicated to phase II trials. Thus, the predictability of this phase for large-scale distribution is driving growth in this segment.
Our in-depth analysis of the global neurology clinical trials market includes the following segments:
|
Indication |
|
|
Phase |
|
|
Study Design |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNeurology Clinical Trials Industry - Regional Synopsis
North America Market Analysis
North America in neurology clinical trials market is likely to account for more than 50.8% revenue share by the end of 2037. Ongoing research and innovation in pharmacology is the major driver behind this region’s proprietorship. Many pharmaceutical, biotech, and academic giants are originating from this landscape, making it a hub of clinical discoveries. For instance, in March 2024, Neurona Therapeutics displayed the newly found clinical data from the phase I and II studies on NRTX-1001 at the annual meeting of American Academy of Neurology (AAN) 2024, held in Denver, Colorado. The evaluation of efficacy and safety of this medicine in drug-resistant focal epilepsy treatment was funded by the California Institute for Regenerative Medicine (CIRM) with USD 8.0 million. Such events attract more companies to invest.
The U.S. is home to a few of the leading initiators and investors in the neurology clinical trials market. The participation in clinical studies from its domestic pioneers is significantly higher than other countries, positioning it at the forefront of this cohort. According to the WHO statistics, 20.5% of the total trial registrations in the world, from 1999 to 2024, belonged to the U.S., accounting for 186,497. This indicates the progressive business environment of this country, on the basis of clinical studies.
Canada is augmenting the neurology clinical trials market with the support from the federal government, in the form of funding and initiatives. They are also investing in extensive R&D projects to cultivate a local innovation network. For instance, in April 2024, Brain Canada secured a USD 80.0 million funding over four years from the Federal Budget 2024. This foundation further aimed at utilizing its unique 1:1 business model to accumulate a total investment of USD 160.0 million by 2028. These proactive efforts are increasing the accessibility of essential assets for neurological research.
APAC Market Statistics
Asia Pacific is one of the fastest growing regions in the neurology clinical trials market with a notable CAGR. This territory has a large number of epilepsy residents, particularly in lower- and middle-income countries (LMICs), which ignites a surge for efficient treatment regimens. According to a WHO report, published in February 2024, 80.0% of the global epileptic population belongs to LMICs (including India, Pakistan, Bangladesh, Indonesia, the Philippines, Vietnam, Lao PDR, Cambodia, and Myanmar). This is dragging the focus of pharmaceutical giants to penetrate their R&D excellence across the region to improve accessibility of therapeutics for a wide range of consumers.
Country-wise Presentation of Clinical Trials [All Types] (1999-2024)
|
Country |
Number of Registrations |
|
China |
135,747 |
|
India |
74,031 |
|
Japan |
65,167 |
Source: WHO Database
India is becoming one of the largest pharmaceutical producers in the world, ensuring a good flow of business in the neurology clinical trials market. The pre-established atmosphere of the country is further attracting foreign investments in neurological research. In addition, integration of advanced technologies in the brain mapping has also been noticed all over the nation. For instance, in December 2024, the Indian Institute of Technology (IIT) Madras unveiled a 3D image of the human fetal brain, having the highest resolution and capturing 5,132 sections. Such revolutionary discoveries boost innovation in neurology, fueling this sector.
China joined this cohort of clinical findings through continuous investments and engagement in the neurology clinical trials market. This nation also suffers from the aging population and widespread CNS. The heightening mortality rates and variability in genetic mutations are pushing its local production house to focus more on pioneering newer therapeutics and remedies. The total R&D expenditure of China was valued at USD 458.0 billion in 2023, exhibiting an 8.1% increment from the previous year and accounting for 2.6% of the national GDP. This signifies the tendency of this country in investing in research activities, particularly in healthcare.
Companies Dominating the Neurology Clinical Trials Landscape
- IQVIA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biogen
- Aurora Healthcare
- GlaxoSmithKline Plc.
- Icon Plc.
- Syneous Health
- Charles River Laboratories
- Med pace
- Covance
- Novartis AG
- Sanofi
- Merck & Co., Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Annovis Bio
- Athira Pharma, Inc.
- Zydus Group
- Eli Lilly and Company
- AstraZeneca
- Supernus Pharmaceuticals, Inc.
- Alzamend Neuro, Inc.
- DANNCE.AI
The highly competitive dynamics of the neurology clinical trials market are fed by the groundbreaking discoveries in treatment methods. Companies are continuously running experimental and observational studies on their newly developed medicines and tools to gain traction in globalization. For instance, in April 2024, Sanofi showcased positive results from phase II data for its solely developed CD40L antibody (frexalimab). The outcomes revealed steady treatment adherence and long-acting efficacy among relapsing multiple sclerosis (MS) patients. Such innovative pathways are fostering new scopes of investment for global leaders, inspiring them to participate in this cohort. Such key players are:
In the News
- In November 2024, DANNCE.AI earned a pre-seed funding of USD 2.6 million, led by LDV Capital and accompanied by Glasswing Ventures, Duke Capital Partners, and Merck Digital Sciences Studio. Its AI-powered biomarkers platform helps attain characterization of the drug effects and optimization of neurological care during clinical trials.
- In October 2024, Alzamend Neuro released the entire data from the phase IIA multiple ascending dose clinical trial on AL001 treatment for Alzheimer’s associated dementia. The results established a strong safety profile confirming the positive topline outcomes, revealed in June 2023.
Author Credits: Radhika Pawar
- Report ID: 7314
- Published Date: Mar 07, 2025
- Report Format: PDF, PPT
